Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A transitional cell carcinoma that arises from the male or female urethra.
Biomarker and diagnostic research for urethra transitional cell carcinoma has been reported in the published literature.
11 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 5 PHASE2, 3 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05987241](https://clinicaltrials.gov/study/NCT05987241) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:01 PM UTC
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study |
PHASE2 |
National Cancer Institute (NCI) |
RECRUITING |
25 publications have been identified in PubMed for urethra transitional cell carcinoma. Research spans Case Report / Case Series (40%), Clinical Trial Publication (32%), and Review / Meta-Analysis (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 10 | 40% |
Clinical study results | 8 | 32% |
Research summaries | 3 | 12% |
Testing and diagnosis research | 2 | 8% |
Laboratory research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Jeon S (2026). [PMID: 42216429](https://pubmed.ncbi.nlm.nih.gov/42216429/). *Vet Q*. [Basic Science / Preclinical]
Lee SH (2026). [PMID: 42188942](https://pubmed.ncbi.nlm.nih.gov/42188942/). *Vet Sci*. [Case Report / Case Series]
Gutti JR (2026). [PMID: 42216724](https://pubmed.ncbi.nlm.nih.gov/42216724/). *Vet Radiol Ultrasound*. [Case Report / Case Series]
Perez-Londoño A (2026). [PMID: 41528510](https://pubmed.ncbi.nlm.nih.gov/41528510/). *World J Urol*. [Clinical Trial Publication]
Chung W (2026). [PMID: 42158320](https://pubmed.ncbi.nlm.nih.gov/42158320/). *Front Vet Sci*. [Case Report / Case Series]
Sahafi P (2026). [PMID: 41941229](https://pubmed.ncbi.nlm.nih.gov/41941229/). *Clin Nucl Med*. [Case Report / Case Series]
De Rose AF (2026). [PMID: 41492217](https://pubmed.ncbi.nlm.nih.gov/41492217/). *Urologia*. [Case Report / Case Series]
Burtz M (2026). [PMID: 41742557](https://pubmed.ncbi.nlm.nih.gov/41742557/). *J Vet Intern Med*. [Clinical Trial Publication]
van der Weyden L (2025). [PMID: 40300500](https://pubmed.ncbi.nlm.nih.gov/40300500/). *J Comp Pathol*. [Case Report / Case Series]
Guevara D (2025). [PMID: 39890191](https://pubmed.ncbi.nlm.nih.gov/39890191/). *Anticancer Res*. [Case Report / Case Series]